Perifosine-a new option in treatment of acute myeloid leukemia?

Janusz Krawczyk, Niamh Keane, Ronan T Swords, Michael O'Dwyer, Ciara L. Freeman, Francis J. Giles

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models, perifosine has an independent cytotoxic potential but also synergizes well with other rationally selected targeted agents. The evidence from clinical trials supporting the use of perifosine in the therapy of leukemias is limited. The optimal dose and schedule have yet to be defined. However, given its favorable toxicity profile and mechanism of action, the therapeutic potential of perifosine should be evaluated in well-designed clinical trials. Areas covered: The role of the phosphatidylinositol-3 kinase (PI3K)/Akt zpathway in normal cells, cancer and leukemias is discussed. The mechanism of action of perifosine and the basic information on the development and chemical properties are summarized. The evidence from in vivo and in vitro studies is presented. The efficacy and side effect profile are summarized. Expert opinion: The safety and tolerability profile of perifosine are satisfactory. The evidence from clinical trials in patients with leukemias is very limited. The preclinical data are encouraging. Perifosine has the potential to play a role in the treatment of leukemias in the future. Its role needs to be confirmed in clinical trials.

Original languageEnglish
Pages (from-to)1315-1327
Number of pages13
JournalExpert Opinion on Investigational Drugs
Volume22
Issue number10
DOIs
StatePublished - Oct 1 2013

Fingerprint

Acute Myeloid Leukemia
Leukemia
Clinical Trials
Therapeutics
Phosphatidylinositol 3-Kinase
Expert Testimony
perifosine
Action Potentials
Appointments and Schedules
Safety
Neoplasms

Keywords

  • Acute myeloid leukemia
  • Chronic lymphocytic
  • Leukemia
  • Perifosine
  • PI3K/AKT pathway
  • Targeted molecular therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Krawczyk, J., Keane, N., Swords, R. T., O'Dwyer, M., Freeman, C. L., & Giles, F. J. (2013). Perifosine-a new option in treatment of acute myeloid leukemia? Expert Opinion on Investigational Drugs, 22(10), 1315-1327. https://doi.org/10.1517/13543784.2013.826648

Perifosine-a new option in treatment of acute myeloid leukemia? / Krawczyk, Janusz; Keane, Niamh; Swords, Ronan T; O'Dwyer, Michael; Freeman, Ciara L.; Giles, Francis J.

In: Expert Opinion on Investigational Drugs, Vol. 22, No. 10, 01.10.2013, p. 1315-1327.

Research output: Contribution to journalArticle

Krawczyk, J, Keane, N, Swords, RT, O'Dwyer, M, Freeman, CL & Giles, FJ 2013, 'Perifosine-a new option in treatment of acute myeloid leukemia?', Expert Opinion on Investigational Drugs, vol. 22, no. 10, pp. 1315-1327. https://doi.org/10.1517/13543784.2013.826648
Krawczyk, Janusz ; Keane, Niamh ; Swords, Ronan T ; O'Dwyer, Michael ; Freeman, Ciara L. ; Giles, Francis J. / Perifosine-a new option in treatment of acute myeloid leukemia?. In: Expert Opinion on Investigational Drugs. 2013 ; Vol. 22, No. 10. pp. 1315-1327.
@article{d10208d516dc479d8a57e5e3c31a0529,
title = "Perifosine-a new option in treatment of acute myeloid leukemia?",
abstract = "Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models, perifosine has an independent cytotoxic potential but also synergizes well with other rationally selected targeted agents. The evidence from clinical trials supporting the use of perifosine in the therapy of leukemias is limited. The optimal dose and schedule have yet to be defined. However, given its favorable toxicity profile and mechanism of action, the therapeutic potential of perifosine should be evaluated in well-designed clinical trials. Areas covered: The role of the phosphatidylinositol-3 kinase (PI3K)/Akt zpathway in normal cells, cancer and leukemias is discussed. The mechanism of action of perifosine and the basic information on the development and chemical properties are summarized. The evidence from in vivo and in vitro studies is presented. The efficacy and side effect profile are summarized. Expert opinion: The safety and tolerability profile of perifosine are satisfactory. The evidence from clinical trials in patients with leukemias is very limited. The preclinical data are encouraging. Perifosine has the potential to play a role in the treatment of leukemias in the future. Its role needs to be confirmed in clinical trials.",
keywords = "Acute myeloid leukemia, Chronic lymphocytic, Leukemia, Perifosine, PI3K/AKT pathway, Targeted molecular therapy",
author = "Janusz Krawczyk and Niamh Keane and Swords, {Ronan T} and Michael O'Dwyer and Freeman, {Ciara L.} and Giles, {Francis J.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1517/13543784.2013.826648",
language = "English",
volume = "22",
pages = "1315--1327",
journal = "Expert Opinion on Investigational Drugs",
issn = "1354-3784",
publisher = "Taylor and Francis Ltd.",
number = "10",

}

TY - JOUR

T1 - Perifosine-a new option in treatment of acute myeloid leukemia?

AU - Krawczyk, Janusz

AU - Keane, Niamh

AU - Swords, Ronan T

AU - O'Dwyer, Michael

AU - Freeman, Ciara L.

AU - Giles, Francis J.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models, perifosine has an independent cytotoxic potential but also synergizes well with other rationally selected targeted agents. The evidence from clinical trials supporting the use of perifosine in the therapy of leukemias is limited. The optimal dose and schedule have yet to be defined. However, given its favorable toxicity profile and mechanism of action, the therapeutic potential of perifosine should be evaluated in well-designed clinical trials. Areas covered: The role of the phosphatidylinositol-3 kinase (PI3K)/Akt zpathway in normal cells, cancer and leukemias is discussed. The mechanism of action of perifosine and the basic information on the development and chemical properties are summarized. The evidence from in vivo and in vitro studies is presented. The efficacy and side effect profile are summarized. Expert opinion: The safety and tolerability profile of perifosine are satisfactory. The evidence from clinical trials in patients with leukemias is very limited. The preclinical data are encouraging. Perifosine has the potential to play a role in the treatment of leukemias in the future. Its role needs to be confirmed in clinical trials.

AB - Introduction: Perifosine is a novel targeted oral Akt inhibitor. In preclinical leukemia models, perifosine has an independent cytotoxic potential but also synergizes well with other rationally selected targeted agents. The evidence from clinical trials supporting the use of perifosine in the therapy of leukemias is limited. The optimal dose and schedule have yet to be defined. However, given its favorable toxicity profile and mechanism of action, the therapeutic potential of perifosine should be evaluated in well-designed clinical trials. Areas covered: The role of the phosphatidylinositol-3 kinase (PI3K)/Akt zpathway in normal cells, cancer and leukemias is discussed. The mechanism of action of perifosine and the basic information on the development and chemical properties are summarized. The evidence from in vivo and in vitro studies is presented. The efficacy and side effect profile are summarized. Expert opinion: The safety and tolerability profile of perifosine are satisfactory. The evidence from clinical trials in patients with leukemias is very limited. The preclinical data are encouraging. Perifosine has the potential to play a role in the treatment of leukemias in the future. Its role needs to be confirmed in clinical trials.

KW - Acute myeloid leukemia

KW - Chronic lymphocytic

KW - Leukemia

KW - Perifosine

KW - PI3K/AKT pathway

KW - Targeted molecular therapy

UR - http://www.scopus.com/inward/record.url?scp=84884261429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884261429&partnerID=8YFLogxK

U2 - 10.1517/13543784.2013.826648

DO - 10.1517/13543784.2013.826648

M3 - Article

VL - 22

SP - 1315

EP - 1327

JO - Expert Opinion on Investigational Drugs

JF - Expert Opinion on Investigational Drugs

SN - 1354-3784

IS - 10

ER -